Filter
68
Filtered Results: 68
Text search:
DNDi
-
Drugs
for
neglected
diseases
initiative
Featured
Recommendations
7
New Publications
7
Language
Document type
Studies & Reports
26
No document type
15
Strategic & Response Plan
6
Resource Platforms
5
Manuals
4
Guidelines
4
Videos
3
Fact sheets
3
Situation Updates
1
Infographics
1
Countries / Regions
Global
10
Latin America and the Carribbean
5
Africa
4
Colombia
3
Ethiopia
3
Kenya
2
West and Central Africa
2
East and Southern Africa
2
Southern Africa
2
Asia
1
North America
1
Uganda
1
Brazil
1
India
1
Authors & Publishers
Publication Years
Category
Studies & Reports
5
Guidelines
3
Leishmaniasis
3
Hepatitis
2
Pediatrics
2
Chagas
2
Statistics
2
NTDs & Others
2
Disease Prevention & Control
2
COVID-19
1
Virology
1
Medical Devices & Equipment
1
Policies
1
Drugs & Medical Equipment
1
Parasitology
1
Human African Trypanosomiasis
1
Non-communicable Diseases
1
HIV & STI
1
Pharmacy & Technologies
1
Toolboxes
Studies & Reports
6
Strategies & Roadmaps
5
Studies & Reports
5
Clinical Aspects & Diagnostics
4
Studies & Reports
4
Capacity Building & Resources
3
Local Action
2
Essential Medicines
2
Capacity Building & Resources
2
Clinical Aspects & Diagnostics
2
Information & Education Material (IEC)
2
Statistics & Facts
2
Overview, Studies & Reports
2
Clinical Aspects, Treatment & Prevention
1
Treatment & Prevention
1
Introduction to Global Health
1
Concepts of Global Health
1
Curricula & Core Competencies
1
Children
1
Health Equity & Equality
1
Country specific documents
1
Long COVID/ Post-COVID Syndrome
1
Advocacy & Communication
1
Prices and Patents
1
Chagas
1
Capacity Building & Resources
1
Information & Education Material (IEC)
1
Information & Education Material (IEC)
1
NTDs General
1
Mycetoma, Chromoblastomycosis & other deep mycosis
1
Information & Education Material (IEC)
1
Asia and Pacific
1
Human Rights & the Right to Health
1
Antiretroviral Treatment ART
1
AMR
1
Reports & Studies
1
This document focuses on making recommendations for the diagnosis and treatment of Chagas disease, an infection caused by Trypanosoma cruzi, the protozoan agent of a systemic parasitic disease. Methodology: These clinical practice guidelines were prepared following the WHO handbook for guideline dev...
WHO and UNITAID
in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach...
In 2007, the Sixtieth World Health Assembly adopted resolution WHA60.13 on control of leishmaniasis, urging Member States, among other actions:
to strengthen prevention, active detection and treatment of cases of both cutaneous and visceral leishmaniasis in order to decrease the disease burde...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insects called triatomines — also known as “kissing bugs” —, foods or beverages contaminated with th...
A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in all continents except Oceania. Representing the most common infectious diseases, NTDs comprise an open-ended list of some 20 parasitic, bact...
The objectives of the meeting were:
1. To step up the commitment of national authorities and technical and financial partners toWHO’s elimination objective for g-HAT.
2. To share achievements, challenges and views on the elimination goal among countries and implementing partners.
3. To assess t...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis...
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...
Lessons from the STEP-TB Project.
Accessed November 2017.
Drug registration in Kenya started in 1982; the process mainly involves an evaluation committee at the Kenya Pharmacy and Poisons Board (PPB) that aims to approve products based on quality, safety and efficacy.
Technology landscape
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...
Meeting Report
27–30 June 2017 Manila, Philippines
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
